Steroid-Refractory Immune-Related Hepatitis Caused by Pembrolizumab with Stage IVB Non-Small Cell Lung Cancer: A Case Report
Introduction: We report the case of a man in his 50s with stage IVB non-small cell lung cancer who developed severe immune-related hepatitis caused by pembrolizumab. Case Presentation: He received carboplatin, pemetrexed, and pembrolizumab as first-line therapy. After four courses, each o...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Karger Publishers
2024-12-01
|
| Series: | Case Reports in Gastroenterology |
| Online Access: | https://karger.com/article/doi/10.1159/000542598 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850133676368592896 |
|---|---|
| author | Tomomi Hamaguchi Makoto Ueno Satoshi Kobayashi Shun Tezuka Manabu Morimoto Terufumi Kato Haruhiro Saito Shinya Sato Junji Furuse Shin Maeda |
| author_facet | Tomomi Hamaguchi Makoto Ueno Satoshi Kobayashi Shun Tezuka Manabu Morimoto Terufumi Kato Haruhiro Saito Shinya Sato Junji Furuse Shin Maeda |
| author_sort | Tomomi Hamaguchi |
| collection | DOAJ |
| description |
Introduction: We report the case of a man in his 50s with stage IVB non-small cell lung cancer who developed severe immune-related hepatitis caused by pembrolizumab. Case Presentation: He received carboplatin, pemetrexed, and pembrolizumab as first-line therapy. After four courses, each of the triplet regimen and maintenance therapy with pemetrexed and pembrolizumab, the patient developed immune-related pneumonitis and colitis. Therefore, pemetrexed and pembrolizumab were discontinued, and 0.5 mg/kg/day prednisolone was started. Despite gradual reduction of the prednisolone to 15 mg/day along with resolution of the pneumonitis and colitis, hepatic dysfunction occurred (elevated serum bilirubin and transaminase levels). We made a diagnosis of immune-related hepatitis based on liver biopsy results and negative results for other causes, such as viral infection. We increased the prednisolone dose to 2 mg/kg/day; however, the hepatic dysfunction was not resolved. Upon sequential methylprednisolone pulse therapy (1,000 mg/day), mycophenolate mofetil, and azathioprine treatment, the hepatic dysfunction plateaued but was not resolved. The patient did not respond to steroids for immune-related hepatitis, developed infectious enteritis owing to a compromised state, and died of sepsis on day 107 after diagnosis of immune-related hepatitis. Conclusion: This case highlights the importance of early diagnosis of steroid-refractory disease, prompt initiation of immunosuppressive agents, and steroid dose reduction in such cases. The changes in liver function during steroid non-response and immunosuppressive drug induction in this case are valuable as a reference for future cases of immune-related adverse event hepatitis. |
| format | Article |
| id | doaj-art-57422530b82145e39ca405cc07ec2839 |
| institution | OA Journals |
| issn | 1662-0631 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Karger Publishers |
| record_format | Article |
| series | Case Reports in Gastroenterology |
| spelling | doaj-art-57422530b82145e39ca405cc07ec28392025-08-20T02:31:55ZengKarger PublishersCase Reports in Gastroenterology1662-06312024-12-01191142110.1159/000542598Steroid-Refractory Immune-Related Hepatitis Caused by Pembrolizumab with Stage IVB Non-Small Cell Lung Cancer: A Case ReportTomomi HamaguchiMakoto UenoSatoshi KobayashiShun TezukaManabu MorimotoTerufumi KatoHaruhiro SaitoShinya SatoJunji FuruseShin Maeda Introduction: We report the case of a man in his 50s with stage IVB non-small cell lung cancer who developed severe immune-related hepatitis caused by pembrolizumab. Case Presentation: He received carboplatin, pemetrexed, and pembrolizumab as first-line therapy. After four courses, each of the triplet regimen and maintenance therapy with pemetrexed and pembrolizumab, the patient developed immune-related pneumonitis and colitis. Therefore, pemetrexed and pembrolizumab were discontinued, and 0.5 mg/kg/day prednisolone was started. Despite gradual reduction of the prednisolone to 15 mg/day along with resolution of the pneumonitis and colitis, hepatic dysfunction occurred (elevated serum bilirubin and transaminase levels). We made a diagnosis of immune-related hepatitis based on liver biopsy results and negative results for other causes, such as viral infection. We increased the prednisolone dose to 2 mg/kg/day; however, the hepatic dysfunction was not resolved. Upon sequential methylprednisolone pulse therapy (1,000 mg/day), mycophenolate mofetil, and azathioprine treatment, the hepatic dysfunction plateaued but was not resolved. The patient did not respond to steroids for immune-related hepatitis, developed infectious enteritis owing to a compromised state, and died of sepsis on day 107 after diagnosis of immune-related hepatitis. Conclusion: This case highlights the importance of early diagnosis of steroid-refractory disease, prompt initiation of immunosuppressive agents, and steroid dose reduction in such cases. The changes in liver function during steroid non-response and immunosuppressive drug induction in this case are valuable as a reference for future cases of immune-related adverse event hepatitis. https://karger.com/article/doi/10.1159/000542598 |
| spellingShingle | Tomomi Hamaguchi Makoto Ueno Satoshi Kobayashi Shun Tezuka Manabu Morimoto Terufumi Kato Haruhiro Saito Shinya Sato Junji Furuse Shin Maeda Steroid-Refractory Immune-Related Hepatitis Caused by Pembrolizumab with Stage IVB Non-Small Cell Lung Cancer: A Case Report Case Reports in Gastroenterology |
| title | Steroid-Refractory Immune-Related Hepatitis Caused by Pembrolizumab with Stage IVB Non-Small Cell Lung Cancer: A Case Report |
| title_full | Steroid-Refractory Immune-Related Hepatitis Caused by Pembrolizumab with Stage IVB Non-Small Cell Lung Cancer: A Case Report |
| title_fullStr | Steroid-Refractory Immune-Related Hepatitis Caused by Pembrolizumab with Stage IVB Non-Small Cell Lung Cancer: A Case Report |
| title_full_unstemmed | Steroid-Refractory Immune-Related Hepatitis Caused by Pembrolizumab with Stage IVB Non-Small Cell Lung Cancer: A Case Report |
| title_short | Steroid-Refractory Immune-Related Hepatitis Caused by Pembrolizumab with Stage IVB Non-Small Cell Lung Cancer: A Case Report |
| title_sort | steroid refractory immune related hepatitis caused by pembrolizumab with stage ivb non small cell lung cancer a case report |
| url | https://karger.com/article/doi/10.1159/000542598 |
| work_keys_str_mv | AT tomomihamaguchi steroidrefractoryimmunerelatedhepatitiscausedbypembrolizumabwithstageivbnonsmallcelllungcanceracasereport AT makotoueno steroidrefractoryimmunerelatedhepatitiscausedbypembrolizumabwithstageivbnonsmallcelllungcanceracasereport AT satoshikobayashi steroidrefractoryimmunerelatedhepatitiscausedbypembrolizumabwithstageivbnonsmallcelllungcanceracasereport AT shuntezuka steroidrefractoryimmunerelatedhepatitiscausedbypembrolizumabwithstageivbnonsmallcelllungcanceracasereport AT manabumorimoto steroidrefractoryimmunerelatedhepatitiscausedbypembrolizumabwithstageivbnonsmallcelllungcanceracasereport AT terufumikato steroidrefractoryimmunerelatedhepatitiscausedbypembrolizumabwithstageivbnonsmallcelllungcanceracasereport AT haruhirosaito steroidrefractoryimmunerelatedhepatitiscausedbypembrolizumabwithstageivbnonsmallcelllungcanceracasereport AT shinyasato steroidrefractoryimmunerelatedhepatitiscausedbypembrolizumabwithstageivbnonsmallcelllungcanceracasereport AT junjifuruse steroidrefractoryimmunerelatedhepatitiscausedbypembrolizumabwithstageivbnonsmallcelllungcanceracasereport AT shinmaeda steroidrefractoryimmunerelatedhepatitiscausedbypembrolizumabwithstageivbnonsmallcelllungcanceracasereport |